| Literature DB >> 26259992 |
Johannes Schiebel1, Nedyalka Radeva1, Helene Köster1, Alexander Metz1, Timo Krotzky1, Maren Kuhnert1, Wibke E Diederich1, Andreas Heine1, Lars Neumann2, Cedric Atmanene3, Dominique Roecklin3, Valérie Vivat-Hannah3, Jean-Paul Renaud3, Robert Meinecke4, Nina Schlinck5, Astrid Sitte5, Franziska Popp4, Markus Zeeb4, Gerhard Klebe6.
Abstract
Fragment-based lead discovery is gaining momentum in drug development. Typically, a hierarchical cascade of several screening techniques is consulted to identify fragment hits which are then analyzed by crystallography. Because crystal structures with bound fragments are essential for the subsequent hit-to-lead-to-drug optimization, the screening process should distinguish reliably between binders and non-binders. We therefore investigated whether different screening methods would reveal similar collections of putative binders. First we used a biochemical assay to identify fragments that bind to endothiapepsin, a surrogate for disease-relevant aspartic proteases. In a comprehensive screening approach, we then evaluated our 361-entry library by using a reporter-displacement assay, saturation-transfer difference NMR, native mass spectrometry, thermophoresis, and a thermal shift assay. While the combined results of these screening methods retrieve 10 of the 11 crystal structures originally predicted by the biochemical assay, the mutual overlap of individual hit lists is surprisingly low, highlighting that each technique operates on different biophysical principles and conditions.Keywords: comparative analysis; endothiapepsin; fragment-based drug discovery; inhibitors; screening methods
Mesh:
Substances:
Year: 2015 PMID: 26259992 DOI: 10.1002/cmdc.201500267
Source DB: PubMed Journal: ChemMedChem ISSN: 1860-7179 Impact factor: 3.466